In recently released news, Cynata Therapeutics announced that it has entered into a strategic alliance with Regience K.K., who will have an exclusive 2-year option to license Cynata’s unique Cymerus™ technology in Japan and certain other Asian countries.
Cynata’s Cymerus™ technology produces clinical-grade mesenchymal stem cells (MSCs) derived from a one-time donation from a single donor, using induced pluripotent stem cells (iPSCs) as the source tissue. This approach allows MSCs to be produced in nearly limitless quantities, eliminates product variability, and allows for lower manufacturing costs.
Cynata is an exciting company to watch, as highlighted by Rodman and Renshaw. To learn more, read the full press release from Cynata Therapeutics, included below. [Read more…]